excessive osteoclastic bone erosion disrupts normal bone remodeling and leads to bone loss in many skeletal diseases, including inflammatory arthritis, such as rheumatoid arthritis (RA) and psoriatic arthritis, periodontitis and peri-prosthetic loosening. Functional control of osteoclasts is critical for the maintenance of bone homeostasis. However, the mechanisms that restrain osteoclast resorptive function are not fully understood. In this study, we identify a previously unrecognized role for G-protein Gα 13 in inhibition of osteoclast adhesion, fusion and bone resorptive function. Gα 13 is highly expressed in mature multinucleated osteoclasts, but not during early differentiation. Deficiency of Gα 13 in myeloid osteoclast lineage (Gα 13 ΔM/ΔM mice) leads to super spread morphology of multinucleated giant osteoclasts with elevated bone resorptive capacity, corroborated with an osteoporotic bone phenotype in the Gα 13 ΔM/ΔM mice. Mechanistically, Gα 13 functions as a brake that restrains the c-Src, Pyk2, RhoA-Rock2 mediated signaling pathways and related gene expressions to control the ability of osteoclasts in fusion, adhesion, actin cytoskeletal remodeling and resorption. Genome wide analysis reveals cytoskeleton related genes that are suppressed by Gα 13 , identifying Gα 13 as a critical cytoskeletal regulator in osteoclasts. We also identify a genome wide regulation of genes responsible for mitochondrial biogenesis and function by Gα 13 in osteoclasts. Furthermore, the significant correlation between Gα 13 expression levels, TNF activity and RA disease activity in RA patients suggests that the Gα 13 mediated mechanisms represent attractive therapeutic targets for diseases associated with excessive bone resorption.
Bone destruction is a major cause of disability associated with many skeletal diseases, such as rheumatoid arthritis (RA), psoriatic arthritis, periodontitis and peri-prosthetic loosening [1] [2] [3] [4] [5] . Osteoclasts are the exclusive cell type that is responsible for bone resorption. Excessive generation of osteoclasts or increased osteoclast activity leads to pathologic bone erosion. Osteoclasts differentiate from the monocyte/macrophage lineage. Osteoclastogenesis is induced by the master osteoclastogenic cytokine receptor activator of nuclear factor-κB ligand (RANKL), which acts in concert with macrophage colony-stimulating factor (M-CSF) and immunoreceptor tyrosine-based activation motif (ITAM)-mediated co-stimulatory signals. Binding of RANKL to its receptor RANK activates a broad range of signaling cascades, including canonical and non-canonical NF-κB pathways; mitogen-activated kinase (MAPK) pathways leading to the activation of AP-1 and CREB transcription factors; and calcium signaling, to induce the expression of key transcription factors Blimp1 and NFATc1 to initiate early stage of osteoclast differentiation 2,6-9 .
Results
Gα 13 is a RANKL inducible gene that controls osteoclast size and resorptive function. Global deletion of Gα 13 expression in mice leads to embryonic lethality 22, 23 . Thus, to determine the role of Gα 13 in osteoclastogenesis, we deleted Gna13 (encoding Gα 13 ) in myeloid lineage osteoclast precursors by crossing Gα 13 flox/flox mice with LysMcre mice that express Cre under the control of the myeloid-specific lysozyme M promoter. We used Gα 13 flox/flox LysMcre(+) mice (hereafter referred to as Gα 13 ΔM/ΔM ) and littermate controls with a Gα 13 +/+ LysMcre(+) genotype (hereafter referred to as wild type (WT)) in the experiments. The bone marrow derived macrophages (BMMs) were used as osteoclast precursors in vitro. We first examined the mRNA and protein expression levels of Gα 13 during osteoclast differentiation induced by RANKL, a master osteoclastogenic cytokine. We observed that low Gα 13 expression levels were maintained throughout the early stage of differentiation and were not highly induced until three days after RANKL stimulation, when the cells generally started fusion and became mature multinucleated giant osteoclasts in cultures ( Fig. 1A,B ). This inducible Gα 13 expression pattern indicates its potential dominant role presumably in the late stage of osteoclast differentiation. Indeed, we found that Gα 13 ΔM/ΔM derived BMMs formed nearly similar number of TRAP-positive multinucleated osteoclasts, but strikingly increased the average osteoclast area to approximately three times of that of the WT cells (Fig. 1C,D) . The average numbers of nuclei per TRAP-positive MNC in Gα 13 ΔM/ΔM osteoclasts were significantly greater than those in WT osteoclasts (Fig. 1D) , indicating a suppressive role for Gα 13 in cell fusion. The Gα 13 ΔM/ΔM osteoclast area began to increase after three days of RANKL stimulation and increased more drastically after four or five days of RANKL stimulation (Fig. 1E ). The super spread Gα 13 ΔM/ΔM multinucleated osteoclasts formed ΔM/ΔM at the indicated days in the presence of RANKL (40 ng/ml). (F) Upper panel: Actin ring formation in the cell culture plates of BMMs derived from WT and Gα 13 ΔM/ΔM mice stimulated with RANKL for five days. Podosome belts are peripherally located. Scale bar, 500 μm. Lower panel: Actin ring formation on dentin slices of BMMs derived from WT and Gα 13 ΔM/ΔM mice stimulated with RANKL for six days. Actin rings are peripherally or internally located. Scale bar, 100 μm. (G) Mineral resorption activity of MNCs derived from WT and Gα 13 ΔM/ΔM mice. The BMMs were cultured on the calcium coated plates with RANKL for seven days. Von kossa staining was performed to detect resorptive pit areas. The representative images of whole well (upper) and 10× magnified field (lower) were shown in the left panel. Scale bars = 500 μm. Quantification of resorptive area relative to whole well area was shown in the right panel. All data are shown as mean ± S.D. ***p < 0.001, n.s., not statistically significant.
F-actin rings (podosome belts) on both tissue culture plates and dentin slices ( Fig. 1F ) and were functional in mineral resorption ( Fig. 1G ). Consistent with the osteoclast area, the resorptive area generated by the Gα 13 ΔM/ΔM cells was much larger than that by the WT osteoclasts ( Fig. 1G) . Notably, the super spread giant osteoclasts were also observed in the Gα 13 ΔM/ΔM mice ( Fig. 2A) . Similarly as in the in vitro cultures, Gα 13 deficiency did not result in different osteoclast numbers in vivo. Significantly, the average osteoclast size and the relative osteoclast surface to bone surface were both enhanced in the Gα 13 ΔM/ΔM mice ( Fig. 2B ). We furthermore examined the serum levels of TRAP and C-terminal telopeptide of type 1 collagen (CTX-I), which are important indicators reflecting osteoclast activity in vivo. As shown in Fig. 2C ,D, both serum TRAP and CTX-I levels were significantly elevated in the Gα 13 ΔM/ΔM mice. We next performed microcomputed tomographic (μCT) analyses in order to examine whether the super spread Gα 13 ΔM/ΔM osteoclasts have effects on the bone phenotype. As shown in Fig. 3 Gα 13 deficiency affects the expression of genes responsible for osteoclast terminal differentiation and function. We next investigated the molecular mechanisms by which Gα 13 regulates osteoclast size and function. We first examined the expression of the genes that play key roles in osteoclast differentiation, fusion and resorptive function. Consistent with the phenotype that Gα 13 does not significantly change osteoclast numbers, Gα 13 deficiency did not alter the induction and expression levels of key osteoclastogenic genes induced by RANKL ( Fig. 4A,B ), such as Fos (encoding c-Fos), Nfatc1 (encoding NFATc1) and Prdm1 (encoding Blimp1), each of which is essential for early osteoclast differentiation. Furthermore, the early osteoclastogenic signaling pathways, such as NF-κB, MAPK and c-Fos, were activated similarly by RANKL between the WT and Gα 13 ΔM/ΔM osteoclast precursors (data not shown). In addition, phosphorylation of AKT in response to M-CSF or RANKL was not affected by Gα 13 ( Supplementary Fig. 1 ). These results collectively support the phenotype that Gα 13 does not affect early stage of osteoclast differentiation. On the other hand, the genes that control osteoclast function, such as CTR (encoding calcitonin receptor), Ctsk (encoding cathepsin K), Acp5 (encoding TRAP) and Itgb3 (encoding integrin β3), were significantly enhanced by RANKL in Gα13 deficient cell cultures (Fig. 4A) . These findings provide a molecular basis for the enhanced bone resorptive function of Gα 13 deficient osteoclasts. Cell fusion process regulates osteoclast size. Following this line, we found that the expression levels of the genes responsible for osteoclast fusion, Dc-stamp (encoding DC-STAMP) and Atp6v0d2 (encoding ATP6v0d2), were higher in Gα 13 ΔM/ΔM osteoclasts than WT cells (Fig. 4A ). The negative regulation of these cell-cell fusion genes by Gα 13 might be responsible, at least partially, for the super spread morphology of Gα 13 ΔM/ΔM osteoclasts with large sizes.
Gα 13 regulates cytoskeletal reorganization in osteoclasts. In addition to gene expression, cytoskeletal reorganization, including cellular adhesion to bone surface and actin ring (podosome belt) formation to generate an isolated resorptive microenvironment (sealing zone), is essential for osteoclasts to effectively execute their bone resorbing function. Moreover, dynamic remodeling of actin cytoskeleton is critical for osteoclasts to cycle actively between resorption-migration-resorption phases on the bone surface. The integrin-or cytokine-mediated cytoskeletal organization is mainly activated via a canonical signaling pathway, which is initiated by c-Src activation. Therefore, we first examined the levels of phosphor-c-Src, an indicator of c-Src activity.
To determine the role of Gα 13 in the activation of c-Src in response to the integrin-mediated adhesion and signaling, we lifted and then re-plated WT or Gα 13 ΔM/ΔM osteoclasts on culture dishes coated with fibronectin, which binds to cellular integrins and activates integrin-medicated signaling. We found that the phosphorylation of c-Src appeared much stronger in the Gα 13 ΔM/ΔM cell cultures in response to adhesion than in the WT cultures, and was maintained at higher levels in the Gα 13 ΔM/ΔM cell cultures ( Fig. 5A ). In addition, Pyk2 phosphorylation is critical for osteoclast adhesion, spreading and bone resorption. Phosphor-Erk and phosphor-FAK levels also play important roles in focal adhesion signaling and the regulation of osteoclast cytoskeletal reorganization 14, 15, 29 . Similarly as the regulation of c-Src activity, Gα 13 deficiency significantly elevated the adhesion-induced phosphorylation levels of Pyk2, FAK and Erk (Fig. 5A ). Next, we investigated whether Gα 13 regulates the activity of Rho GTPases, the downstream effectors of these signaling pathways and central players in cytoskeleton reorganization. We found that Gα 13 deficiency increased the GTP bound RhoA levels in response to osteoclastic adhesion ( Fig. 5B) , consistent with the upstream signaling enhancement. The GTP-Rac1 level was not much affected by the absence of Gα 13 (data not shown). These results indicate that Gα 13 is an inhibitor of RhoA activity during cytoskeletal remodeling in osteoclasts. Rho-associated kinase Rock2 is a key downstream effector of RhoA. In parallel to the changes of RhoA activity, the phosphorylation levels at S1366 of Rock2, an indicator of its activation, were enhanced by Gα 13 deletion (Fig. 5A ). These results further support an inhibitory role for Gα 13 in controlling the RhoA-Rock2 pathway during cytoskeleton organization in osteoclasts.
Furthermore, we investigated whether Gα 13 regulates dynamic remodeling of actin cytoskeleton. To address this question, we tested the cytokine-mediated actin ring re-organization of osteoclasts. The WT and Gα 13 ΔM/ΔM osteoclast cultures were starved of M-CSF and RANKL. Five hours later, as expected with the knowledge of the importance of cytokine in cytoskeleton organization, the actin rings disappeared in both WT and Gα 13 ΔM/ΔM osteoclast cultures on tissue culture plates or on dentin slices ( Fig. 5C ,D, time 0 after starvation). Upon re-stimulation with M-CSF and RANKL, Gα 13 deficiency enabled the cells to reorganize the actin cytoskeleton to form actin rings within 5 minutes, which was much faster than the WT cells that needed 30 minutes ( Fig. 5C ). Genome wide analysis reveals that Gα 13 regulates key genes responsible for cytoskeleton, mitochondrial biogenesis and function. To further explore molecular mechanisms by which Gα 13 acts on osteoclast function, we performed gene expression profiling using high throughput sequencing of RNA (RNAseq) with the WT and Gα 13 ΔM/ΔM osteoclast precursors at baseline and the corresponding osteoclasts after RANKL stimulation for five days to identify genes regulated by Gα 13 . We next performed Gene Ontology (GO) www.nature.com/scientificreports www.nature.com/scientificreports/ analysis of the up-regulated genes in the RANKL stimulation condition in the Gα 13 ΔM/ΔM osteoclasts. Consistent with the phenotype of the enhanced ability of Gα 13 ΔM/ΔM osteoclasts for adhesion and actin ring organization, GO analysis revealed highly significant upregulation of genes involved in cytoskeleton, ruffle and adhesion ( Fig. 6A ). We further extracted the gene expression values and found that 307 cytoskeleton-related genes ( Fig. 6B , Supplementary Table 1 ), including GIT1 and Itgb3, were significantly elevated by Gα 13 deficiency. These genome wide analysis data provided another important piece of evidence for the regulatory role of Gα 13 in cytoskeleton reorganization. The profound effect of Gα 13 on the cytoskeleton gene expression indicates that Gα 13 likely functions as a central cytoskeleton regulator. As expected, the genes in charge of osteoclast differentiation, such as Nfatc1, Fos, Prdm1, were not affected by Gα 13 deficiency (data not shown).
Surprisingly, we found that the most enriched gene sets were involved in mitochondrial structural complex and mitochondrial respiratory chain complexes in Gα 13 deficient osteoclasts ( Fig. 6A) , indicating a negative regulation of mitochondrial biogenesis and function by Gα 13 . We extracted these genes from the RNA-seq data and confirmed 51 mitochondrial related genes (Figs 6B, 7A) that were highly enhanced in the Gα 13 ΔM/ΔM osteoclasts. www.nature.com/scientificreports www.nature.com/scientificreports/ These findings obtained from genome wide analysis highlight an exciting and promising novel regulatory network in osteoclasts mediated by Gα 13 on mitochondrial regulation. Since osteoclast resorption is a highly energy consuming process, the enhanced osteoclast activities in the absence of Gα 13 , including cytoskeleton organization, remodeling and resorption, would require and be supported by increased energy supply from mitochondria. While we were preparing our manuscript, the Zou and Teitelbaum group showed that mitochondria mediated cytoskeleton organization contributes to osteoclast resorptive function 30 . In osteoclasts, we also found that Gα 13 deficiency enhanced mitochondrial DNA content ( Fig. 7B ), reflecting an increase in mitochondrial biogenesis. These results, together with the enhanced expression of genes for controlling mitochondrial biogenesis and 7A ), indicate that Gα 13 might suppress mitochondrial biogenesis and function, which provide energy supply in osteoclasts. Our findings are corroborated by a recent study demonstrating that Gα 13 negatively regulates mitochondrial gene expression and function in muscle cells 31 . These results together suggest a novel function for Gα 13 in the regulation of mitochondria in different cell types. Since mitochondria-provided energy is essential for every cellular function, there is a technical limitation to suppress mitochondrial function while without affecting cellular activity. Thus, we cannot exclude the possibility that the enhanced mitochondrial gene expression is an associated phenomenon along with the enhanced osteoclast function in the Gα 13 deficient osteoclasts. Nonetheless, although it is unclear whether the regulation is direct or indirectly associated, our results at least indicate that the genes related with mitochondrial biogenesis and function are regulated by Gα 13 . Gα 13 expression is down-regulated in RA and inversely correlated with RA activity. Having established that Gα 13 negatively regulates osteoclast resorptive function, we wished to examine whether Gα 13 expression levels are altered in the RA disease, in which excessive osteoclastic bone resorption is a hallmark of the characteristic pathogenesis of the disease. Similarly as in the mouse system, Gα 13 expression was highly induced in the human osteoclast precursors derived from CD14(+) peripheral blood monocytes (PBMCs) after a few days of RANKL stimulation ( Supplementary Fig. 2 ). Strikingly, Gα 13 expression level was decreased in the CD14(+) PBMCs isolated from RA patients compared to healthy donors (Fig. 8A ). Our findings suggest that the down-regulated Gα 13 expression in RA cells can result in the loss of a constraint on osteoclast function based on our data from mouse cells and that this effect could contribute to the pathogenic mechanism mediated by Gα 13 in the inflammatory bone resorption. Given the importance of TNF in the pathogenesis of RA and the resounding success of TNF blockade therapy (TNFi) in the treatment of RA, we first examined the Gα 13 effect on the TNF-mediated inflammatory osteoclast formation. In inflammatory conditions, TNF often acts in synergy with RANKL to promote osteoclastogenesis. To mimic the in vivo condition, we treated the BMMs with TNF in the presence of RANKL, and found that Gα 13 deletion also significantly promoted the areas of the TRAP (+) multinucleated osteoclasts ( Supplementary Fig. 3 ), indicating that Gα 13 plays an inhibitory role in controlling osteoclast spreading in TNF-mediated inflammatory conditions. Furthermore, TNF blockade therapy of RA patients with a humanized antibody that specifically blocks TNF activity (Enbrel) strikingly elevated Gα 13 expression levels in the PBMCs after one or two month-treatment ( Fig. 8B) . Moreover, the therapeutic reduction of TNF activity by TNFi significantly increased Gα 13 expression levels in each individual RA patient after TNFi treatment (Fig. 8C ). TNFi therapy decreases TNF activity in the pathogenesis of RA. Therefore, Gα 13 expression levels were www.nature.com/scientificreports www.nature.com/scientificreports/ negatively correlated with TNF activity in RA. In parallel, TNFi significantly decreased the osteoclast areas of PBMCs (Fig. 8D ). Further statistical analysis revealed a strong inverse correlation (Pearson's r = −0.653) between the levels of Gα 13 expression and the sizes of osteoclasts formed in RA PBMC cell cultures (Fig. 8D) . Given the feedback effect of Gα 13 on osteoclast resorptive function, these findings support the idea that low Gα 13 levels in RA contribute to the pathologic osteoclastic bone erosion. Gα 13 expression levels are inversely correlated with the RA disease activity and thus could be a predictor of both osteoclast function and disease activity of RA.
Discussion
The adult skeleton undergoes constant and dynamic remodeling to maintain bone homeostasis, which is tightly regulated by osteoclast-mediated bone resorption and osteoblast/osteocyte-mediated bone formation 17, 32, 33 . This tightly-regulated balance is disrupted in the chronic inflammation and disease settings such as found in RA and periodontitis, which are some of the most common pathological conditions associated with bone loss. The balance disruption leads to excessive bone resorption and suppressed bone formation 1, 3, 4 . Clinical inhibition of osteoclast differentiation suppresses osteoclastic resorption, but meanwhile it often reduces osteoclast abundance. This pathological change dampens normal bone remodeling, resulting in insufficient bone formation in www.nature.com/scientificreports www.nature.com/scientificreports/ multiple disease settings. Recent evidence shows the importance of appropriate maintenance of osteoclast abundance in balancing bone remodeling and stimulating new bone formation [16] [17] [18] [19] . Thus, it comes under the spotlight to investigate how to control osteoclast function, which has not been fully understood. In this study, we identify a previously unrecognized role for Gα 13 in inhibition of osteoclast function. Gα 13 is selectively highly expressed in multinucleated osteoclasts during osteoclastogenesis. Gα 13 functions as a brake that restrains the signaling pathways and gene expression to control the ability of osteoclasts in fusion, adhesion, cytoskeletal remodeling and resorption. Deficiency of Gα 13 leads to an osteoporotic bone phenotype attributed to super spread osteoclasts with enhanced bone resorptive function. Gα 13 deletion does not affect osteoblast numbers and surfaces in mice ( Supplementary Fig. 4 ). The close correlation between Gα 13 expression levels, TNF activity and RA disease activity in RA patients suggest that the Gα 13 -pathway represents an attractive therapeutic target to prevent bone destruction in inflammatory diseases associated with excessive bone erosion.
Osteoclast cytoskeleton organization and remodeling, mainly reflected by actin ring and ruffled border formation, is crucial for the osteoclast bone resorptive ability. The defects in the canonical signaling pathways that positively regulate cytoskeleton organization, such as c-Src or Pyk2 deletion, often lead to abnormal actin ring assembly in osteoclasts with contracted morphology and low ability to resorb bone [12] [13] [14] [15] . In contrast to these well-studied positive regulatory signals, the feedback regulatory mechanisms involved in cytoskeleton organization and osteoclast function remain poorly understood. The present study identifies Gα 13 as a newly identified negative regulator of osteoclast cytoskeleton organization and function. Gα 13 is a RANKL inducible inhibitor that generally reaches high expression levels after RANKL stimulation for a few days, but has marginal expression at early stage of differentiation before three days. The unique expression pattern of Gα 13 could explain its minimal effects on osteoclast differentiation.
Deletion of Gα 13 leads to enlarged super spread osteoclasts both in vitro and in vivo. These Gα 13 deficient osteoclasts have comparable survivability to WT cells (data not shown), but their abilities of fusion, adhesion, cytoskeleton organization and resorption are significantly enhanced. The underlying mechanisms include the negative regulation of gene expression that is in charge of cell-cell fusion and osteoclast function, c-Src, Pyk2, Erk and FAK mediated signaling and downstream activation of RhoA and ROCK2, as well as a unique mitochondrial regulation by Gα 13 . Thus, the profound regulation of cytoskeleton by Gα 13 places Gα 13 in a central knot in the regulatory network mediating osteoclast function. Osteoclasts execute high energy-consuming activities, such as cellular adhesion, migration and bone resorption, all of which require appropriate cytoskeleton organization. To support sufficient energy consumption for these cellular activities, osteoclasts are a mitochondria-rich cell type. Thus, mitochondrial regulation would presumably affect cytoskeleton organization. Indeed, evidence 30 show that inhibition of mitochondrial function for a short period in osteoclasts almost completely disrupts actin ring structure. In this study, we identified the genome wide regulation of genes involved in mitochondrial biogenesis and function by Gα 13 in osteoclasts. This Gα 13 mediated regulation of mitochondria is also observed in muscle cells 31 . Gα 13 mediated mitochondrial function might contribute to the mechanisms by which Gα 13 restrains osteoclast cytoskeleton organization and function. It is however a puzzle how exactly Gα13 modulates gene expression in mitochondria. Conversely, cytoskeletal organization can influence mitochondrial network structure and function in certain cells, for example, mitochondria move along microtubules or actin filaments and actin filaments help determine the locations of mitochondria in neurons 34 . Thus, it seems that there is a cross-regulation between mitochondria and cytoskeleton. Although the mechanisms of the bi-directional regulation remain less understood, it is possible that the unique cytoskeletal structure in osteoclasts could regulate mitochondrial distribution and function. These interesting questions have not been explored and future studies would address whether and how mitochondria and cytoskeleton cross talk with each other. Overall, the findings from our genome wide study and another group 31 indicate a novel function of Gα 13 that contributes to the regulatory network of mitochondria and open a new avenue to study the biological significance and underlying mechanisms by which Gα 13 regulates mitochondria and cytoskeleton.
As a G-protein, Gα 13 can act through small Rho GTPases, such as Rac or RhoA, depending on cell types 20, 25 . In osteoclasts, we found that Gα 13 functions through RhoA to further act on downstream Rock2. The Gα 13 mediated regulation of the RhoA-Rock2 pathway was also observed in muscle cells 31 . However, it is unclear how Gα 13 links to different GTPases and regulates their activity differently in various cells, presumably due to the various interactive proteins and guanine-nucleotide exchange factors (GEFs) in different settings 20, 25, 35 . The upstream GPCRs that connect to Gα 13 , have not been identified in osteoclasts. We searched the GPCRs that were reported to play a part in osteoclasts, such as GPR103, EBI2, GPR68 and GPR55, and found that GPR55 is associated with Gα 13 36,37 . However, functional analysis in vitro could not provide clear evidence that GPR55 and Gα 13 work in the same pathway in osteoclasts (data not shown). It will be of interest and significance for future studies to investigate and uncover upstream regulators and receptors associated with Gα 13 in osteoclasts. Our study identified unique downstream factors, pathways and novel mitochondrial mediated mechanisms by which Gα 13 controls osteoclast cytoskeleton organization and function. Gα 13 , as a novel negative regulator, plays a key role in the maintenance of osteoclast function. Given the deregulated Gα 13 levels in RA and its correlation with RA disease activity, targeting Gα 13 and its mediated pathways would provide alternative therapeutic strategies to control osteoclast function and excessive bone resorption associated with many diseases.
Materials and Methods
Animal study and analysis of bone phenotype. We generated mice with myeloid specific deletion of Gα 13 by crossing Gα13 flox/flox mice 23 with mice with a lysozyme M promoter-driven Cre transgene on the C57BL/6 background (known as LysMcre; The Jackson Laboratory). Gender-and age-matched Gα 13 flox/flox LysMcre(+) mice (referred to as Gα 13 ΔM/ΔM ) and their littermates with LysMcre(+) genotype as wild-type controls (referred to as WT) were used for experiments. X-ray analysis was conducted using a high-resolution soft X-ray system (Faxitron Model MX-20) at 26 kV. Micro-computed tomography (µCT) analysis was conducted to evaluate bone www.nature.com/scientificreports www.nature.com/scientificreports/ volume and 3D bone architecture using a Scanco µCT-35 scanner (SCANCO Medical) as described 38, 39 . 2-monthold mouse femora were fixed in 10% buffered formalin and scanned at 6 µm resolution. Proximal femoral trabecular bone parameters were analyzed using Scanco software according to the manufacturer's instructions and the American Society of Bone and Mineral Research (ASBMR) guidelines. Femur bones were subjected to sectioning, TRAP staining, toluidine blue staining and histological analysis. Mouse serum TRAP was measured with MouseTRAP ™ (TRAcP 5b) ELISA (Immunodiagnostic Systems (IDS)) and serum CTX-I was measured using Mouse CTX/Collagen C-Terminal Telopeptide ELISA Kit (LifeSpan BioSciences) according to manufacturer's instructions. The osteomeasure software (OsteoMetrics, Atlanta, GA, USA) was used for bone histomorphometry using standard procedures according to the program's instruction. All of the experiments were conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All animal studies were approved by the Hospital for Special Surgery Institutional Animal Care and Use Committee (IACUC), and Weill Cornell Medical College IACUC.
Reagents. Murine M-CSF, murine TNF and soluble human RANKL were purchased from PeproTech (Rochy Hill, NJ, USA). Recombinant Fibronectin was purchased from Sigma-Aldrich. Alexa Fluor ® 488 phalloidin (A12379) was purchased from Invitrogen (Carlsbad, CA, USA).
Cell culture. To obtain bone marrow macrophages (BMMs), mouse bone marrow cells were harvested from tibiae and femora of age and gender-matched mutant and control mice and cultured for 3 days in α-MEM medium (Thermo Fisher Scientific) with 10% FBS (Atlanta Biologicals), glutamine (2.4 mM, Thermo Fisher Scientific), Penicillin-Streptomycin (Thermo Fisher Scientific) and CMG14-12 supernatant (condition medium, CM), which contained the equivalent of 20 ng/ml of rM-CSF and was used as a source of M-CSF as described 38 . The attached BMMs were scraped, seeded at a density of 4.5 × 10 4 /cm 2 , and cultured in α-MEM medium with 10% FBS, 1% glutamine and CM for overnight. Except where stated, the cells were then treated with or without optimized concentrations of RANKL (40 ng/ml) or TNF (40 ng/ml) in the presence of CM for times indicated in the figure legends. Culture media were exchanged every three days. Human osteoclast cultures were performed as described previously 40 . Briefly, peripheral blood mononuclear cells (PBMCs) from whole blood of healthy volunteers or RA patients were isolated by density gradient centrifugation using Ficoll (Invitrogen Life Technologies, Carlsbad, CA). CD14+ cells were purified from fresh PBMCs using anti-CD14 magnetic beads (Miltenyi Biotec, Auburn, CA) as recommended by the manufacturer. Human monocytes were cultured in α-MEM medium with 10% FBS in the presence of M-CSF (20 ng/ml; PeproTech, Rocky Hill, NJ) for 2 days to obtain monocyte-derived macrophages, which were further cultured with RANKL for osteoclast differentiation. The RA PBMCs were from RA patients (age ≥ 18 and <70 years) who fulfilled American College of Rheumatology (ACR) 2010 RA classification criteria with disease duration <5 years and were under TNFi therapy for the first time (Enbrel, 25 mg weekly). Experiments with human cells were approved by Nanfang Hospital (China) and the Hospital for Special Surgery (USA) Institutional Review Board. Informed consent (PBMC collection) was obtained from all healthy volunteers and RA patients. All experiments were performed in accordance with relevant guidelines and regulations. TRAP staining was performed with an acid phosphatase leukocyte diagnostic kit (Sigma-Aldrich) in accordance with the manufacturer's instructions.
Actin cytoskeleton reorganization assay. 2 × 10 4 WT or Gα 13 ΔM/ΔM BMMs were cultured on 96 well plates for three days or 6 × 10 3 WT or Gα 13 ΔM/ΔM BMMs on dentin slices (0.4 cm in diameter) for six days with CM (equivalent of 20 ng/ml of rM-CSF) and 40 ng/ml RANKL. The cells were then starved in the culture medium without FBS, M-CSF and RANKL for 5 hours, and were re-stimulated with 20 ng/ml M-CSF and 40 ng/ml RANKL for 0, 5, 15 or 30 minutes as indicated in figure legends. Phalloidin staining was performed in accordance with manufacturer's instructions. Briefly, the cells were fixed with 4% PFA/PBS for 10 min at room temperature (RT) and washed with PBS. Then, the cells were permeabilized in 0.5% Triton X-100/PBS for 5 min followed by blocking with 1% BSA/PBS for 20 min at RT. The cells were then incubated with Alexa Fluor ® 488 phalloidin (Invitrogen, 1:500 dilution) for 20 minutes. After washing with PBS, fluorescent signals were detected with a fluorescent microscope. The osteomeasure software (OsteoMetrics, Atlanta, GA, USA) was used for the quantitative analysis of actin ring/podosome belt formation in the cell cultures using standard procedures according to the program's instruction.
In vitro adhesion assay. To prepare fibronectin-coated plates, 6 well plates were incubated with 1 ml of fibronectin (10 μg/ml) per each well for 2 hours at 37 °C. The plates were then washed with PBS for 3 times and were ready for adhesion assay. 8 × 10 6 WT or Gα13 ΔM/ΔM BMMs were cultured with CM (equivalent of 20 ng/ml of rM-CSF) and 40 ng/ml RANKL on 10 cm culture dishes for 3 days. The cells were then starved in the culture medium without FBS, M-CSF and RANKL for 5 hours, and were lifted by scraper. 2 × 10 6 cells were then plated on the fibronectin-coated 6 well tissue culture plates (attached cells) or left in αMEM as suspension conditions for 15 min or 30 min, followed by immunoblot analysis or GTP-RhoA pull down assay.
Mineral resorption pit assay. The mineral resorption activity of osteoclasts was examined using 96-well Corning Osteo Assay Surface Plates (Sigma-Aldrich). BMMs were plated at a seeding density of 2 × 10 4 per well and incubated with CM (equivalent of 20 ng/ml of rM-CSF) and RANKL (40 ng/ml) for 8 days, with medium exchange every day once mature round shaped-osteoclasts were observed. After removing cells with 10% bleach solution, the minerals were stained with von kossa to visualize the formation of resorptive pits. The resorptive area was analyzed using ImageJ (National Institutes of Health, Bethesda, MD, USA).
Reverse transcription and real-time pCR.
For quantification of mRNA, reverse transcription and real-time PCR were performed as previously described 40 . Briefly, DNA-free RNA was obtained using the RNeasy www.nature.com/scientificreports www.nature.com/scientificreports/ Mini Kit (QIAGEN) with DNase treatment, and total RNA was reverse transcribed using a First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA). Real-time PCR was performed in triplicate using Fast SYBR ® Green Master Mix and the QuantStudio5 Real-Time PCR System (Applied Biosystems, Foster City, CA) following the manufacturer's protocol. Gene expression was normalized relative to the gene expression levels of Glyceraldehyde-3-phosphate dehydrogenease (Gapdh). The primer sequences are available upon request.
RNA-seq and Bioinformatics analysis.
Total RNA was extracted using RNeasy Mini Kit (QIAGEN) following the manufacturer's instructions. True-seq RNA Library preparation kits (Illumina) were used to purify poly-A+ transcripts and generate libraries with multiplexed barcode adaptors following the manufacturer's instructions. All samples passed quality control analysis using a Bioanalyzer 2100 (Agilent). RNA-seq libraries were constructed per the Illumina TrueSeq RNA sample preparation kit. High-throughput sequencing was performed using the Illumina HiSeq 4000 in the Weill Cornell Medical College Genomics Resources Core Facility. RNA-seq reads were aligned to the mouse genome (mm10) using STAR 41 . HTseq 42 . was subsequently used to count reads in features and then EdgeR 43 was used to estimate the transcript abundances as TPM (transcripts per million) values. Heatmaps were generated by the pheatmap package in R. Gene Ontology (GO) analysis was performed with Panther Classification System 44, 45 input with the RANKL-regulated genes that were more highly expressed in Gα13 ΔM/ΔM cells than WT cells (≥1.5 fold). Gα13 regulated pathways by the GO analysis were ranked based on the p values. p values were calculated following the program's instructions. RNA-seq data (accession #GSE116550) have been deposited in NCBI's Gene Expression Omnibus (http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE116550).
Immunoblot analysis. Total cell extracts were obtained using lysis buffer containing 150mMTris-HCl (pH 6.8), 6% SDS, 30% glycerol, and 0.03% Bromophenol Blue; 10% 2-ME was added immediately before harvesting cells. Cell lysates were fractionated on 7.5% SDS-PAGE, transferred to Immobilon-P membranes (Millipore), and incubated with specific antibodies. Western Lightning plus-ECL (PerkinElmer) was used for detection. For immunoblotting, anti-NFATc1 (556602, 1:1000 dilution) was from BD Biosciences. Anti-Blimp1 (sc-47732, 1:1000 dilution), anti-Gα13 (sc-410, 1:500 dilution), anti-RhoA (sc-418), and anti-p38α (sc-535, 1:1000 dilution) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-pyk2 (06-559, 1:1000 dilution) was from EMD Millipore. Anti-phospho-Pyk2 (Try402) (#3291, 1:1000 dilution), anti-phospho-Akt (Ser473) (#9271, 1:1000 dilution), anti-phospho-Akt (Thr408) (#2965, 1:1000 dilution), anti-Akt (#9272, 1:1000 dilution), anti-phospho-ERK (Ser473) (#9101, 1:1000 dilution), anti-ERK (#9102, 1:1000 dilution), anti-phospho-Src family (Tyr416) (#2101, 1:1000 dilution) were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA). Anti-phospho-Rock2 (Ser1366, 1:500 dilution) is from GeneTex.
Purification of GST-PBD protein.
The GST-PBD plasmid 27 was purified as described 46 . Briefly, fusion protein containing RhoA-binding domain Rhotekin (RhBD, amino acids 7-89) fused with GST were produced in Eschericia coli BL21 cells. After isopropylthigalactoside (IPTG) induction for 4 hrs at 30 °C, pellets of bacteria were resuspended in Bacterial lysis buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1 μg/mL aprotinin and then sonicated. Cell lysates were incubated with GST beads (ThermoFisher) for 2 hrs at 4 °C. The beads were wash 5 times with washing buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM PMSF, and 1 μg/mL aprotinin. The beads were aliquoted in wash buffer with 10% v/v glycerol (1:1 slurry) and stored at −80 °C.
Affinity-precipitation of cellular GTP-RhoA (pulldown assay). The suspension and attached osteoclasts from adhesion assay were lysed in a buffer containing 50 mM Tris/HCl, pH 7.5, 1 mM EDTA, 500 mM NaCl, 10 mM MgCl 2 , 1% Triton X-100, and protease inhibitors (4 µg/ml leupeptin, 5 µg/ml apropeptin, 1 mM PMSF, 5 mM NaF, 5 mM sodium orthovanadate and protease inhibitor cocktail). Cell lysates were clarified by centrifugation at 15 000 g at 4 °C for 10 min. Equal volumes of lysates were incubated with 50 µg GST-RBD fusion protein at 4 °C for 1 hr while rotating. After pulldown, the beads were centrifuged at 250 g for 2 min and 4 °C and then washed five times with a buffer containing 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 10 mM MgCl 2 , 1% Triton X-100, 10 µg/ml leupeptin, 10 µg/ml apropeptin and 1 mM PMSF. The pulled down active RhoA proteins were analyzed by SDS-PAGE followed by immunoblotting against RhoA (Santa Cruz Biotechnology, sc-418). ImageJ was used to quantify the immunoblot band density that reflects the amount of proteins, and the relative amount of GTP-bound RhoA was normalized to the total amount of RhoA in cell lysates for the comparison of RhoA activity in different samples. statistical analysis. Statistical analysis was performed using Graphpad Prism ® software. The two-tailed Student's t test was applied when there were only two groups of samples. In the case of more than two groups of samples, one-way ANOVA was used with one condition, and two-way ANOVA was used with more than two conditions. ANOVA analysis was followed by Post hoc Bonferroni's correction for multiple comparisons. p < 0.05 was taken as statistically significant; *p value < 0.05, **p value < 0.01 and ***p value < 0.001. Data are presented as the mean ± SD as indicated in the figure legends.
